Prospects for gene therapy in corneal disease

Jun, Albert S.; Larkin, Frank

doi:10.1038/sj.eye.6700565

Cited by 49 publications

(30 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3,4,[23][24][25] Nonviral vectors, although safe, are generally very inefficient and do not produce long-term gene expression in ocular tissues. 23,26 Adenovirus, the first vector to be systematically explored for gene transfer to the cornea, 5,27 is an efficient vector suitable for both mitotic and post-mitotic cells, but its inherent immunogenicity can limit the duration of transgene expression.…”

Section: Discussionmentioning

confidence: 99%

Lentivirus-mediated gene transfer to the rat, ovine and human cornea

et al. 2007

View full text Add to dashboard Cite

Gene therapy of the cornea shows promise for modulating corneal transplant rejection but the most appropriate vector for gene transfer has yet to be determined. We investigated a lentiviral vector (LV) for its ability to transduce corneal endothelium. A lentivector expressing enhanced yellow fluorescent protein (eYFP) under the control of the Simian virus type 40 early promoter (LV-SV40-eYFP) transduced 80-90% of rat, ovine and human corneal endothelial cells as detected by fluorescence microscopy. The kinetics of gene expression varied among species, with ovine corneal endothelium showing a relative delay in detectable reporter gene expression compared with the rat or human corneal endothelium. Vectors containing the myeloproliferative sarcoma virus promoter or the phosphoglycerate kinase promoter were not significantly more effective than LV-SV40-eYFP. The stability of eYFP expression in rat and ovine corneas following ex vivo transduction of the donor cornea was assessed following orthotopic corneal transplantation. Following transduction ex vivo, eYFP expression was maintained in corneal endothelial cells for at least 28 days after corneal transplantation in the sheep and 460 days in the rat. Thus, rat, ovine and human corneal endothelial cells were efficiently transduced by the LV, and gene expression appeared stable over weeks in vivo. Gene Therapy (2007) 14, 760-767.

show abstract

Section: Discussionmentioning

confidence: 99%

Lentivirus-mediated gene transfer to the rat, ovine and human cornea

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Gene delivery to the corneal epithelium is greatly facilitated because of relatively rapid cell division and the anatomical fact that corneal epithelial and stromal layers are on the top surface of the cornea [5]. Unfortunately, the cornea is also protected from noxious substances in the environment by rapidly secreted tears to flush its surface as well as an impermeable epithelium with tight junctions between cells [2].…”

mentioning

confidence: 99%

Eye drop delivery of nano‐polymeric micelle formulated genes with cornea‐specific promoters

Tong

Chang

Liu

et al. 2007

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…[214][215][216][217][218] Studies have been performed in the context of both CNV and corneal allograft rejection.…”

Section: Experimental Gene Therapy Strategiesmentioning

confidence: 99%

Treatments for Corneal Neovascularization: A Review

Gupta¹,

Illingworth²

2011

Cornea

View full text Add to dashboard Cite

Corneal neovascularization (CNV) may be a physiological response to various stimuli, but a chronic and persistent upregulation of neoangiogenesis can result in pathological CNV. Pathological blood vessels are immature and lack structural integrity, predisposing the cornea to lipid exudation, inflammation, and scarring. CNV can therefore become a potentially blinding condition. In this review, we frame CNV in an epidemiological perspective, consider risk factors for CNV, provide an overview of CNV pathogenesis, and consider the impact of CNV on corneal transplantation. We consider treatments that are of largely historical interest, before reviewing contemporary medical and surgical treatments. Within medical treatments, we report on steroids, nonsteroidal anti-inflammatory agents, antivascular endothelial growth factor agents, and cyclosporine. Within surgical treatments, we report on the use of lasers, photodynamic therapy, superficial keratectomy, and diathermy/cautery-based treatments.

show abstract

Prospects for gene therapy in corneal disease

Cited by 49 publications

References 26 publications

Lentivirus-mediated gene transfer to the rat, ovine and human cornea

Lentivirus-mediated gene transfer to the rat, ovine and human cornea

Eye drop delivery of nano‐polymeric micelle formulated genes with cornea‐specific promoters

Treatments for Corneal Neovascularization: A Review

Contact Info

Product

Resources

About